Innovent Biologics, Inc. · HKEX:1801
Innovent Biologics — Investor Day (September 2021)
147 slides from Innovent Biologics's investor day presentation, Sep 28, 2021
Slide 1: Transforming to Global Innovation: Innovent 2021 Investor Day
Transforming to Global Innovation 以创新为基石，走全球化道路 Innovent 2021 Investor Day September 2021 To develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people
Slide 2: Disclaimer
Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of Innovent Biologics (“Innovent” “we,” “us” or “our”), our bu
Slide 3: Agenda
Agenda To p i c s 01 02 03 Company Overview & R&D and Globalization BD Collaboration Strategy Strategy Dr. Michael Yu Dr. Yong-Jun Liu Mr. Blake Salisbury Founder, Chairman and CEO President SVP 04 05 06 Commercialization Senior Management Pipeline Update Update & Strategy Panel Discussion Dr. Hui Z
Slide 4: Company Overview & Strategy
Anna Agenda To p i c s 01 02 03 Company Overview & Company Overview & R&D and Globalization Strategy Strategy Dr. Michael Yu Strategy Dr. Yong-Jun Liu BD Collaboration Mr. Blake Salisbury Founder, Chairman and CEO President VP 04 05 06 Commercialization Senior Management Pipeline Update Update & Str
Slide 5: Innovative Pharmaceutical Industry Has Achieved Breakthrough Lately
In the past 10 years Innovative Pharmaceutical Industry Has Achieved Breakthrough Lately Blockbuster drugs New modalities Novel targets Keytruda ADC PD-1 / PD-L1 Opdivo CAR-T CD47 COVID-19 vaccines mRNA LAG3 Anti-IL4 mAb Bispecific antibody TIGIT … … … Novel targets and new modalities fuel the evo
Slide 6: Global Capital Market Favors Biotech's Long-term Growth
Global Capital Market Favors Biotech’s Long-term Growth Nasdaq Biotech Index (NBI) / S&P 500 Performance History Top 10 Index Weights as of May 14, 2021 (%) 3000.0% NBI zoomed c.700% up to its peak NBI bounced back strongly in March 2000, only to experience during the 2010s, increasing a dramati
Slide 7: Core Competences Drive Leading Biopharma Players' Sustainable Growth
Core Competences Drive Leading Biopharma Players’ Sustainable Growth Companies that ride on the trend of the booming global innovative drug industry… Examples of successful companies Great strategy Integrated platform Risk diversified portfolio To expand To catch up with To develop portfolio to cove
Slide 8: Inflection Point for Chinese Innovative Drugs to Advance into Global Market
Now Comes the Inflection Point for Chinese Innovative Drugs to Advance into Global Market 2021 & beyond China innovation 2.0 2010 - 2020 Era of advancing to global innovation China innovation 1.0 Platform 2000 - 2010 ● Leading companies are biopharma aiming to achieve potential China pre-innovation
Slide 9: Innovent is Transforming to a World-class Biopharma Company
Benefit from global & China biotech industry development Innovent is Transforming from a China Leading Biopharma to a World-class Biopharma Company Confidential Copyright© 2021 Innovent Biologics 9
Slide 10: Innovent's First 10-year Growth: Built Solid Foundation
Innovent’s First 10-year Growth: Built Solid Foundation to Pursue Global Innovation Key R&D Capability Pipeline Globalization transformations From China to world-class From fast-follow to BIC/FIC From domestic to global 5 21 60000L 22 6000 commercial clinical capacity in global experienced products
Slide 11: Robust Pipeline in Oncology and Non-oncology with 26 Assets
Innovent Has Built a Robust Pipeline in Both Oncology and Non- oncology with 26 Valuable Assets at Different Clinical Stages • TYVYT® (sintilimab injection) • IBI348 (BCR-ABL/KIT), NDA • IBI376 (PI3Kδ) • High potential IO targets: accepted by NMPA in 1H - r/r FL, pivotal Phase 2 ongoing - CD47 (IBI1
Slide 12: State-of-the-art Manufacturing Facilities
State-of-the-art Manufacturing Facilities Designed to, Built with, and Operating at International Standards M1b Facility Total capacity in the future: 60,000 L 36,000L 24,000L Manufacturing facilities with a total of 60,000L capacity providing competitive advantage on the production cost of our pr
Slide 13: Comprehensive Collaboration with Regional and Global Leading Players
Comprehensive Collaboration with Regional and Global Leading Players as Their Partner-of-Choice Collaborations with global player: Continued collaborations with global pharmaceutical and biotech companies • Access to Roche’s bispecific antibody and • Total deal value exceeds US$2.5bn1 Universal CART
Slide 14: Strategy Transformation
Strategy Transformation Driven by innovation, developed through Robust and high-quality pipeline Global standard cGMP biologics globalization manufacturing facility in China Confidential Copyright© 2021 Innovent Biologics 14
Slide 15: R&D Capability Transformation
R&D Capability Transformation: From Leading in China to World-class R&D Capability to Pursue Global Innovation Drug Discovery Drug Development ● China industry-leading, fully-integrated clinical development platform and capability ● Specialty in antibody discovery ● Initial global development of lea
Slide 16: Pipeline Transformation: From Fast-follow to BIC/FIC
Pipeline Transformation: From Fast-follow to Potential BIC/FIC with Differentiation ● More blockbuster products launched in global markets 4 Future Global ● A global premier biopharmaceutical company with integrated platform on global territory blockbuster CD47 LAG3 ● Capture the most high-potential
Slide 17: Business Globalization
Business Globalization: Our Ambition is to Target the Larger Global Markets To launch products China clinical Large global market size globally development advantage Innovent has become a To enhance in- top biopharma house global clinical company in China with China Global development industry leadi
Slide 18: Near Term Catalysts
Near Term Catalysts We continue to deliver significant milestones while we are becoming a global innovation powerhouse Global Commercial Worldwide Drug Discovery Development Portfolio Partnerships ● Innovent Academy has ● Established a global ● Commercial 3,000 in ● Collaboration established wet lab
Slide 19: Long-Term Vision
Long-Term Vision Developing core competiveness 2030 based on strategic vision, global 2025 talent and strong execution • More commercialized • Expanded products, including 2020 commercialized first-in-class products in China blockbusters launched globally • Multiple products • 4 commercialized appro
Slide 20: R&D and Globalization Strategy
Anna Agenda To p i c s 01 02 03 R&D and Globalization Company Overview & R&D and Globalization Strategy BD Collaboration Strategy Strategy Dr. Michael Yu Dr. Yong-Jun Liu Mr. Blake Salisbury Founder, Chairman and CEO President VP 04 05 06 Commercialization Senior Management Pipeline Update Update &
Slide 21: Innovent has 26 Clinical-stage Assets in the Robust Pipeline
Innovent has 26 Clinical-stage Assets in the Robust Pipeline Status IND Products Target (s) Therapeutic Area Commercial Rights Pre-clinical Phase1 Phase 2 Phase 3 NDA Launched Filed Accepted TYVYT® (sintilimab injection） PD-1 Oncology Worldwide NDA approved: Dec 24, 2018 BYVASDA® (bevacizumab inject
Slide 22: Four Clusters of Molecules with Global Blockbuster Potential
We Focus on 4 Clusters of Molecules with Global and Blockbuster Potential for POC Next Generation I-O Targets Ophthalmology LAG-3 CD47 TIGIT VEGF-based Bispecific IBI302 (VEGF/C3) IBI110 (LAG-3) IBI188 (CD47) IBI939 (TIGIT) IBI324 IBI323 (PD-L1/LAG-3) IBI322 (PD-L1/CD47) (VEGF/undisclosed) IBI321 (P
Slide 23: Our Champion Team Pushing the POC of 4 Clusters
This is Our Champion Team who are Pushing the POC of 4 Clusters of Molecules First PD-1 inhibitor included in NRDL The Only PD-1 inhibitor proven to be efficacious in the first-line treatment of five major types of cancer (nsq NSCLC/sq NSCLC/HCC/ESCC/GC) One year faster than competitor to obtain
Slide 24: China Team and Global Team Delivering the POCs
Our China team and Global Team will Work Together to Deliver the POCs of 4 Clusters of Molecules Collaborate Seamlessly to Win Globally China Product Development Global Clinical Development (n=800 --> 1600 by 2023) (n=150 by 2023) Medical Science Clinical Preclinical & Strategy Operation Research GP
Slide 25: 2030 Layout
2030 Layout Push the Boundary of Science to Deliver Next Generation Medicine
Slide 26: 80+ New Projects Launched by Innovent Academy
ADC 80+ New Projects Launched ADC ISAC T/NK engager by Innovent Academy in Immuno-Cytokine 2020 - 2021 Pro-drug Polymeric IgG Multi-specific Ab CAR-T Small Molecule mAb Confidential Copyright© 2021 Innovent 26
Slide 27: Worldwide-based Discovery Facilities
From Molecule to Blockbuster: Worldwide-based Discovery Facilities ‘ ' US lab established in 1H 2021 Shanghai R&D center \ in operation by 2023 \
Slide 28: Our Scientific Advisory Board
Our Scientific Advisory Board Lawrence Fong, M.D. Lewis L. Lanier, Ph.D. Carlos Garcia-Echeverria, Ph.D. The Efim Guzik Distinguished Chairman of the SAB An accomplished drug discovery Professor in Cancer Biology in the The US National Academy of Sciences scientist and pharma executive, Hele
Slide 29: What is Blockbuster?
What is Blockbuster? Meet Patient unmet Life-saving Science/Technology medical needs Life-changing Breakthrough
Slide 30: Top 20 Blockbuster Sales Revenue in 2020
Top 20 Blockbuster Sales Revenue in 2020 Unit: $Billion 19.8 Antibody 12 14.4 Peptide 1 Small Mole 7 12.1 9.4 9.2 8.0 7.9 7.9 7.3 6.8 6.3 6.1 5.9 5.4 5.1 4.9 4.6 4.6 4.5 4.3 Humira Keytruda Revlimid Imbruvica Eliquis Stelara Opdivo Eylea Biktarvy Xarelto Enbrel Avastin Prevnar Ibrance Trulicity Remi
Slide 31: Innovent Academy Focus: Patient Unmet Needs
Innovent Academy Focus: Patient Unmet Needs Challenges Solutions No responders Translational medicine (resistance / relapse) guided multi-targets Unmet medical New technologies to target Undruggable target undruggable targets needs No target Research to discover targets Confidential Copyright© 2021
Slide 32: Innovent Academy Focus
Innovent Academy Focus Antibody protein Immunology Business engineering Cancer biology Development Talents: From 30 to 120 Talents: From 40 to 150
Slide 33: Immunology Related Therapies has Large Market Potential
Immunology Related Therapies has Large Market Potential Remote communication via cytokines Cognate communication via surface receptor and ligand Target Molecule Market size Target Molecule Market size TNFα Adalimumab & etc. $ 39Bn PD-1 Pembrolizumab & etc. $ 23Bn Global market IL-23 Ustekinumab & et
Slide 34: Projects Supported by Protein and Antibody Technologies
The 80 New Projects Supported by State-of-the-art Protein and Antibody Technologies… Monoclonal ADC Multi- T/NK Immuno- Polymeric ADC ISAC Pro-drug antibody traditional specific engager cytokine IgG
Slide 35: Antibody Drug Conjugates: Next Generation ADCs
Antibody Drug Conjugates: Next generation ADCs with Improved Therapeutic Windows ADC - cytotoxic ADC - ISAC ● Dual tumor antigen targets provide better therapeutic window and can prevent tumor escape − Bispecific/Biparatopic ADCs − More specific and better safety ● Novel cytotoxic linker-payloads ●
Slide 36: Bi-/Multi-specific Antibody
Bi-/Multi-specific Antibody: Simultaneously Target Multiple Antigens and Pathways Bispecific Trispecific Tetraspecific TAA1 TAA2 TAA1 TAA1 TAA2 TAA2 TAA3 InnoBody® InnoBody® InnoBody® TAA3 TAA4 ● TAA toolbox cover multiple solid tumor types ● Simultaneously block multiple oncogenic drivers ● TAA-dep
Slide 37: T/NK Cell Engager
T/NK Cell Engager: Harness the Power of Immune Cells to Improve Cancer Therapy Dual-Targeting Cytokine-armed Co-stimulating T cell Engager NK cell engagers Engager TAA TAA1 TAA NK stimulator Co-stimulator αCD3 InnoBody® InnoBody® InnoBody® TAA2 Cytokine ● Broad applications in Heme and solid tumors
Slide 38: Immunocytokines
Immunocytokines: Powerful Immune Activators to Turn Up the Heat on Tumors TAA TAA1 TAA2 TAA1 TAA2 Cytokine Cytokine1 Cytokine2 Cytokine ● Structure guided cytokine engineering platform ● Different formats for unique biological MOAs ● Expand and activate cytotoxic lymphocytes within TME ● Selectively
Slide 39: Pro-drug: Tumor Microenvironment Activation
Pro-drug: Tumor Microenvironment Activation to Avoid Systemic Toxicity CIRCULATION TUMOR (Inactive) (Active) protease protease Tumor Microenvironment protease cleavage ● Minimal activity in circulation or healthy tissues ● Selectively “turn on” in protease enriched tumor ● Expand therapeutic window
Slide 40: BD Goes beyond Our Territories
BD Goes beyond Our Territories Big Molecules Small Molecules Cell Therapy Technology Platform
Slide 41: Any Modality, Any Disease with Blockbuster Potential
We Focus on Transformative, Global, any Modality, any Disease with Blockbuster Potential mRNA Gene-editing PROTAC Al Technology Stem cell Technology
Slide 42: Well Planned Portfolio Pipeline for Accelerated Growth
Accelerated Growing Global Portfolio Supported by R&D Engine with Novel Science and Technologies Solid foundation with de-risked, abundant 80+ Innovent Academy Well Planned Portfolio Pipeline for Accelerated Growth portfolio for early success Projects Global FIC/BIC Well planned global portfolio for
Slide 43: Push the Boundary of Science, Deliver Life-changing Medicines
Push the Boundary of Science, Deliver Life-changing Medicines Confidential Copyright© 2021 Innovent 43
Slide 44: BD Collaboration
Anna Agenda To p i c s 01 02 03 Strategy BD Collaboration Company Overview & R&D and Globalization Strategy BD Collaboration Dr. Michael Yu Dr. Yong-Jun Liu Mr. Blake Salisbury Founder, Chairman and CEO President VP 04 05 06 Commercialization Senior Management Pipeline Update Update & Strategy Panel
Slide 45: Innovent BD Organization Footprint: Experienced Global BD Team
Innovent BD Organization Footprint: Experienced Global BD Team Dr. Yong-Jun Liu, President US & China BD Team Europe BD Team Blake C. SALISBURY Astrid Maria DAHL Head of BD US & China Chief Operating Officer USA (Utah) and Head, Europe Europe (London) 30 years of biopharma experience 20 years of
Slide 46: Summary of BD Pipeline
Summary of BD Pipeline – Extend the Breadth of Our Pipeline in Various Ways Molecule Partner Target Pre-clinic IND IND Approval Ph1 Ph2 Pivotal/Ph3 NDA/Market In-license China Rights - from Global Companies PEMAZYRE Incyte FGFR1/2/3 Parsaclisib Incyte PI3Kδ GLP-1/GCGR Lilly Oxymodulin IBI-397 Alecto
Slide 47: BD Empowers Internal R&D While Fueling Globalization
BD Empowers Our Internal R&D While Fueling Globalization Through Multiple Partnering Modalities Building Platforms Unlocking Value of Regional Pioneering MNC for the Future Best-in-class Partnering In-house R&D Partnerships Biotech Assets “Lilly/Innovnet” most comprehensive Partnering to Build Capab
Slide 48: Overall BD Strategy Complementary to Globalization Strategy
Overall BD Strategy is Complementary to Innovent’s Globalization Strategy Strengthen Technical Going From Domestic Strengthen Global Product Portfolio Core-Competency to Global Market Early/Mid Stage – GLOBAL RIGHTS Late Stage- CHINA RIGHTS Proactively in-license China molecules to GLOBAL COMMERCIAL
Slide 49: Fully-integrated Platform Allows Strategic Partnerships Worldwide
Agenda Innovent’s Fully- integrated Platform and Validated Capabilities Allow Us to Continuously Establish Strategic Partnerships Worldwide Copyright© 2021 Innovent Biologics 49
Slide 50: Strategic Collaboration Expansion with Lilly on Tyvyt
Strategic Collaboration Expansion with Lilly on Tyvyt® for Ex-China Market “It is the first time for a China innovative, marketed large molecule medicine to be out-licensed to a global pharmaceutical company” Deal Value: >US$1bn Highlights Will receive… • Upfront payment— US$200m • May 2021: Tyvyt’s
Slide 51: Strategic Collaboration with Roche
Further Enhance R&D Capability by Strategic Collaboration with Roche “Creative platform deal structure that gives Roche first opportunity to develop and commercialize outside of China” Deal Value: >US$2bn Will access… Strategic Benefits • Certain Roche technologies in the discovery and development o
Slide 52: Multi-Product Strategic Collaboration with Incyte for China
Multi-Product Strategic Collaboration with Incyte for China “Demonstrated Innovent’s ability, as biologics company, to effectively drive development of small molecules as well” Deal Value: ~US$300m Will receive… Strategic Benefits • Development and commercialization rights to 3 late-stage Incyte pro
Slide 53: Creative Collaboration with BOLT
Further Enhance R&D Capability by Creative Collaboration with BOLT “Creative platform deal, where parties share global rights in different ways for different products” Deal Value: ~US$15m Will co-develop… Strategic Benefits • 3 ISACs up to PoC in China and provide antibody components for 3 ISACs • S
Slide 54: Unlock Value of Union's Best-in-Class Asset in Autoimmune
Unlock Value of Union’s Best-in-Class Asset in Autoimmune “Potential BIC PDE4 inhibitor for inflammatory dermatology diseases with strong differentiation and broad target indications” Deal Value: ~US$267Mn Will be granted… Strategic Benefits • Exclusive rights to research, develop and commercialize
Slide 55: KRAS G12C Collaboration with Genfleet
Strategic KRAS G12C Collaboration with Genfleet for Global Rights “Importantly, includes opt-in rights for global Deal Value: ~US$312m development and commercialization” Will obtain • Development and commercialization rights in Strategic Benefits China • Additional opt-in rights for global developme
Slide 56: Late Stage China Partnership with AnHeart
Late Stage China Development & Commercial Partnership with AnHeart “Adding a late stage and potential best-in-class asset into our portfolio and creating commercial synergies” Deal Value: ~US$189m Strategic Benefits Will obtain… • Potential first-in-China and global best-in-class next generation ROS
Slide 57: China Commercial Collaboration with Ascentage
China Commercial Collaboration with Ascentage in Late Stage Assets “A new model for China biopharmaceutical companies to work together to bring additional benefit to patients.” Will establish multifaceted strategic collaboration in … • The joint commercialization of IBI348 (olverembatinib) in China,
Slide 58: BD as Complementary Pillar to In-house R&D
As an Important Complementary Pillar to Our In-house R&D, BD helps Facilitate Innovent’s Global Innovation Strategy Copyright© 2021 Innovent Biologics 58
Slide 59: Pipeline Update
Anna Agenda To p i c s 01 02 03 Pipeline Update Company Overview & R&D and Globalization BD Collaboration Strategy Strategy Dr. Michael Yu Dr. Yong-Jun Liu Mr. Blake Salisbury Founder, Chairman and CEO President VP 04 05 06 Commercialization Senior Management Pipeline Update Update & Strategy Panel
Slide 60: Innovent Oncology Development
1. Oncology Strategy Highlights 2. TA Development Strategy 3. I-O Portfolio Development Innovent Oncology 4. Executive Capacity Development Confidential Copyright© 2021 Innovent 60
Slide 61: Product Development Strategy is Critical to Blockbuster Success
Product Development Strategy is Critical to the Success of Blockbuster Drugs Advanced lines First lines Adjuvant Product Development Molecule Blockbuster Breast cHL Cancer Pre-clinical Commercial Colorectal NSLCC Cancer • Indication decides the market size of a drug US$ 30B SCLC Bladder • Product de
Slide 62: Superior Execution with Integrated Platform in Product Development
Innovent’s Superior Execution with Integrated Platform Capability in Product Development Internal External Bioanalysis Science Strategy Execution Regulatory Companion diagnostics Talent Digitalization Management Specialization System • Build up ladder • Clear work Ecosystem …text • AI management of
Slide 63: Product Development Competence as Clinical Powerhouse
Innovent Can Leverage Product Development Competence to be the Clinical Powerhouse for Global Innovation Bring China innovative drugs Accelerate global innovative into global market Clinical Powerhouse drugs into China market On the way to bring Partner-of-choice for China innovative MNC and oth
Slide 64: Oncology Development Strategy Overview
Innovent Oncology Development Strategy Overview Innovent Oncology Development Strategy Key Enablers Focus IO-resistant / failed population Concentrated around high opportunity MoA First-in-class MoAs CD47, LAG3, TIGIT & etc. Focus on assets with global rights Expanding China and ex-China footprint U
Slide 65: Innovent Oncology Development
1. Oncology Strategy Highlights 2. TA Development Strategy 3. I-O Portfolio Development Innovent Oncology 4. Executive Capacity Development Confidential Copyright© 2021 Innovent 65
Slide 66: Innovent Lung Cancer Pipeline Strategy
Innovent Lung Cancer Pipeline Strategy Confidential Copyright© 2021 Innovent 66
Slide 67: Leading Position in Lung Cancer
Leading Position in Lung Cancer Listed Clinical in progress (China) Clinical progress (Global) Segment Asset Preclinical IND Phase I Phase 1b/2 Pivotal2/Phase 3 NDA Approved 1L nsq Sintilimab (PD-1) 1L sq Sintilimab (PD-1) Advanced NSCLC IBI305 (VEGF) 2L sq Sintilimab (PD-1) NSCLC 1L IBI939 (TIGIT)
Slide 68: Innovent Strategy in NSCLC
Innovent Strategy in NSCLC: Delicate Tactics for Significantly Important Indication Highland ● Dominate Sintilimab’s leadership position in China ● Supported by Sintilimab + next ● Unlock franchise potentials by internal generation IOs synergy and leveraging external (TIGIT/LAG3/CD47) with global co
Slide 69: Strategy in Driver Gene (+) NSCLC
Strategy in Driver Gene (+) NSCLC: Covers Majority Population of Subgroups Mutational landscape in Chinese NSCLC1 EGFRmt NSCLC ROS1+ NSCLC KRAS G12c+ NSCLC Sintilimab + Byvasda (anti-VEGF) + Taletrectinib 1L, IBI351 chemo (ORIENT-31) 2L crizotinib KRAS-G12Ci EGFR TKI failed failed 1: In US, KRAS G12
Slide 70: IBI351: Potential Best-in-class KRAS G12C Inhibitor
IBI351: a Potential Best-in-class KRAS G12C Selective Inhibitor MOA and Differentiation IBI351: KRAS G12C Inhibitor ● Positioned as the important component of Innovent Drug the historically ‘undruggable’ target solid tumor cancer franchise including lung − KRAS G12C can be inhibited covalently ● Pot
Slide 71: IBI351: Clinical Development Status
IBI351: Clinical Development Status Phase1 Phase2 Pivotal/Phase 3 IBI351 (KRAS G12C) Phase 1 study ongoing Mono: 2L KRAS G12C+ NSCLC Planning, upon Phase 1 data +Sintilimab: 1L KRAS G12C+ NSCLC Planning, upon Phase 1 data +EGFR: 1L KRAS G12C+ CRC Planning, upon Phase 1 data Potentials: Adjuvant KRAS
Slide 72: Innovent Hematologic Malignancy Pipeline Overview
Innovent Hematologic Malignancy Pipeline Overview Confidential Copyright© 2021 Innovent 72
Slide 73: Hematologic Malignancies Pipeline Status
Hematologic Malignancies Pipeline Status Pivotal Phase 2 / Segment Asset Preclinical IIT Phase I Phase 1b/2 Launched Phase 3 HL r/r IBI308 (PD-1) B CELL LYMPHOMA 1L IBI301 (CD20) ≥3L IBI326 (BCMA CAR-T) BTD designation for r/r MM MM 1L IBI326 (BCMA CAR-T) FL ≥2L IBI376 (PI3K) BTD designation for r/r
Slide 74: IBI376: Targeting PI3Kδ in B-cell Lymphomas
IBI376: Targeting PI3Kδ in B-cell Lymphomas Parsaclisib (IBI376) is a potent and selective next-generation PI3Kδ inhibitor, potentially a Best-in-class molecule Efficacy-ORR, % Medicine Target Co. FL (n) MZL (n) Parsaclisib PI3Kδ Incyte 77.7% (120) 58% (100) (US data) Idelalisib PI3Kδ Gilead 54% (72
Slide 75: IBI326: BCMA CAR-T for r/r Multiple Myeloma
IBI326: BCMA-targeting CAR-T Cell Therapy for r/r Multiple Myeloma (MM) BCMA is a validated highly potent target for MM A fully human CAR contributes to a reduced immunogenicity and an unprecedented median persistence • IBI326 is currently under pivotal phase 2 in China, of CAR T cells: 308 and NDA
Slide 76: IBI326: Promising Preliminary Data
IBI326: Shown Promising Preliminary Data Depth and durability of response to IBI326 are Failure to triumph: those who relapsed impressive after prior murine BCMA CAR ● 100% ORR with 72% CR/sCR ● ¾ sCR and ¼ VGPR in the murine BCMA CAR exposed ● One-year probability of PFS& OS: 58.3% & 75% ● IBI326 e
Slide 77: IBI188: Potential Best-in-class CD47 mAb
IBI188: Potential Best-in-class, Highly-potent CD47 mAb MOA and Differentiation IBI188: anti-CD47 mAb IBI-188: anti-CD47 mAb ● Induce tumor clearance by macrophage, mechanistically synergize with other tumor clearance therapy(chemo, PD-1,HMA,etc.) ● Positioned to be fully execute synergistic effect
Slide 78: IBI188: Targeting CD47 in AML and MDS
IBI188: Targeting CD47 in AML and MDS Phase 1b Study: 1L MDS (IBI188C301) IBI188 dose regimen Study Identifier: NCT04485065 Maintenance dose Primary Endpoint: 1L MDS Azacitidine + IBI188 Priming dose IBI188 30mg/kg QW Safety, CR, DOCR Azacitidine 75mg/m2 D1-D7 every IBI188 0.1-15mg/kg cycle, 28 days
Slide 79: IBI188: Case Reports in AML and MDS
IBI188: Case Reports in AML and MDS IBI188B201 AML trial IBI188C301 MDS trial 180 Platelet 250 Platelet ● 64 y/o Male, 1L unfit AML ● 63 y/o Male, 1L EB2 ● Baseline characteristics: ● Baseline characteristics: 150 ‐ FAB classification: M4 ‐ ECOG: 1 ‐ WHO classification: NOS Hemoglobin ‐ IPSS-R: High
Slide 80: Broad Coverage on Hematologic Tumor Indications
Innovent Has Broad Coverage on Hematologic Tumor Indications Lymphoma Myeloid neoplasm Multiple Myeloma cHL TYVYT HALPRYZA IBI326 CLL MM (PD-1) (CD20) (BCMA CAR-T) DLBCL & FL HALPRYZA IBI188 New pipeline AML & MDS (CD20) (CD47) FL & MZL IBI376 Lisaftoclax AML (PI3K) (BCL2) lymphoma IBI110 Olverembat
Slide 81: Innovent Oncology Development
1. Oncology Strategy Highlights 2. TA Development Strategy 3. I-O Portfolio Development Innovent Oncology 4. Executive Capacity Development Confidential Copyright© 2020 Innovent Biologics 81
Slide 82: I-O Pipeline Layout: High Opportunity MOA
I-O Pipeline Layout: Concentrated around 8 High Opportunity MOA New targets + PD-(L)1 I-O + I-O New targets I-O + Targeted therapy IBI110 IBI323 (LAG3) (PD-L1/LAG3) I-O Bi-specific/Multi-specific IBI939 IBI321 Early stage population (TIGIT) (PD-1/TIGIT) Efficacy improvement in first line PD-1 resist
Slide 83: Increasing Novelty of the mAb and bi-Abs
Waves of IO and IO-based Molecules to be Explored under Industry-leading Integrated Product Development Platform Innovent Academy Projects Phase 1 Preclinical Increasing Novelty of the mAb and bi-Abs PD-L1/LAG3 …… PoC Stage PD-1/TIGIT …… PD-1/CD137 LAG3 SIRPα PD-L1/CD47 CTLA-4 CD47 PD-1/HER2 Prelimi
Slide 84: Development of I-O Broadens Portfolio Potential
Development of I-O Significantly Broadens Our Portfolio Potential for Cancer Treatment Broader Treatment Lines Adjuvant/Neo-adjuvant First Line Later lines PD-1 CLDN PD-1 Resistant KRAS G12C 18.2 PD-1 Insensitive LAG3 ROS1 Combo Potential CTLA-4 PD-L1/CD47 CD47 FGFR1/2/3 PD-1/HER2 TIGIT PD-1/PD-L1 T
Slide 85: Sintilimab: PD-1 Cornerstone Molecule
Sintilimab: PD-1 Continues to be the Cornerstone Molecule for Cancer Treatment Globally Era 1 Era 2 ● PD-1 will continue to be the cornerstone molecule for KRAS cancer treatment globally G12C LAG3 VEGF ● A comprehensive and well diversified portfolio (I-O Sintilimab + Chemo mAb, multi-specifics, tar
Slide 86: Sintilimab for 1L ESCC
Sintilimab for 1L ESCC: a Potential New 1L PD-1 Treatment for Global Patients ORIENT-15 Study Overall Survival PD-L1 CPS ≥ 10 All Randomized mOS: 17.2 mo mOS: 16.7 mo （15.5-NC） （14.8-21.7） mOS ：13.6 mo mOS ：12.5 mo （11.3-15.7） （11.0-14.5） • Improvement in OS and PFS are Statistically Significant • S
Slide 87: Sintilimab for 1L GC: Overall Survival
Sintilimab for 1L GC: The First Phase 3 Trial in Chinese GC Population That Achieved Significant OS Benefits ORIENT-16 Study Overall Survival PD-L1 CPS ≥ 5 All Randomized mOS ： 18.4 mo mOS ：15.2 mo mOS ：12.9 mo （14.6-NC） mOS ：12.3 mo （12.9-18.4） （11.1-15.4） （11.3-13.8） 34% 23% Risk Deduct- Risk Dedu
Slide 88: Sintilimab for 1L GC: Progression Free Survival
Sintilimab for 1L GC: a Potential New Standard 1L Treatment Option for GC Patients ORIENT-16 Study Progression Free Survival PD-L1 CPS ≥ 5 All Randomized mPFS ： 7.7mo mPFS ：7.1 mo （6.9-9.7） （6.8-8.5） mPFS ：5.8 mo 37% mPFS ：5.7 mo 36% （5.5-6.9） Risk Deduct- （5.5-6.9） Risk Deduct- ion of ion of Progre
Slide 89: Sintilimab: Pushing the Boundary of PD-1's Potential
Sintilimab: Keep Pushing the Boundary of PD-1’s Potential Sintilimab (PD-1) Pre-clinics Ph1 Ph1b/Ph2 Pivotal Ph2/Ph3 NDA/Approved 1L Cancer Treatment Five major types: 1L nsqNSCLC, 1L sqNSCLC, 1L HCC, 1L ESCC, 1L GC Adjuvant/Neoadjuvant Non Small Cell Lung Cancer Global Phase 3 Planning Combo with C
Slide 90: IBI110: Highly Potent LAG3 mAb
IBI110: Highly Potent LAG3 mAb to Synergize with Sintilimab MOA and Differentiation IBI110: anti-LAG3 mAb ● LAG3 is expressed on activated T cells, natural killer cells, B cells and plasmacytoid dendritic cells. It's principal ligand is MHC class II, to which it binds with higher affinity ● High aff
Slide 91: IBI110: Promising Preliminary Efficacy Signal
IBI110: Shown Promising Preliminary Efficacy Signal Higher binding affinity to human T cells ● Phase 1 study of IBI110 monotherapy and combo with sintilimab was completed, with no DLT ● Clinical anti-tumor activity was observed both in mono and in combo dose group 10000 IgG4 8000 Relatlimab FL2-H MF
Slide 92: IBI110: Clinical Development Status
IBI110: Clinical Development Status IBI110 LAG3 Ph1 Ph1b/Ph2 Ph3 Ph1 Study Differentiated development strategy for LAG3 Dose escalation 2021-Q2 Completed RP2D • Reverse PD-1/-L1 resistant • Improve efficacy in 1st line setting Cohort expansion-13 cohorts • Expand PD-1 inhibitor indications Palliativ
Slide 93: IBI110: Global Study Design - 1L ES-SCLC
IBI110: Global Study Design - 1L ES-SCLC Phase II study of IBI110 in combination with sintilimab and chemotherapy in the treatment of first-line extensive SCLC Post PoC Ph2 PoC Ph3 MRCT Started in 2021.H2 Major Inclusion Criteria IBI110 200mg+sintilimab 200mg +EP IBI110 200mg+sintilimab 200mg +EP •
Slide 94: IBI322: First-in-class PD-L1/CD47 Bispecific
IBI322: First-in-class PD-L1/CD47 Bispecific Antibody MOA and Differentiation IBI322: Anti-PD-L1/CD47 ● Synergistic anti-tumor effect of innate and adaptive immunity ● Superior toxicity profile: tumor-specific delivery of aCD47 antagonist would generate better anti-tumor effects with fewer side effe
Slide 95: IBI322: Promising Efficacy Signal in Lung Cancer
IBI322: Promising Efficacy Signal in Lung Cancer Cases Baseline Week8 Baseline Week6 28Jun2021 25Aug2021 26Jul2021 09Sep2021 ● Subject 03016, nsqNSCLC, multiple lines of chemo + ● Subject 01002, nsqNSCLC, 1-line chemotherapy failed bevacizumab failed (including pemetrexed, platinum, docetaxel, (peme
Slide 96: IBI322: Clinical Development Status
IBI322: Clinical Development Status IBI322 CD47/PD-L1 Ph1 POC Pivotal Dose escalation RP2D Reverse PDx resistant 2/3L IO failed NSCLC 2L IO failed HCC Improve efficacy in IO insensitive indications TKI resistant NSCLC PoC readout expected from early-2022 Platinum resistant ovarian cancer Cervical ca
Slide 97: Innovent Oncology Development
1. Oncology Strategy Highlights 2. TA Development Strategy 3. I-O Portfolio Development Innovent Oncology 4. Executive Capacity Development Confidential Copyright© 2021 Innovent 97
Slide 98: Fully Integrated Global Clinical Development Team
Product Development Organization: Fully Integrated Global Clinical Development Team to Win Globally China Product Development Global Product Development (n=800+) (n = 150 by 2023) Lei Qian, Hui Zhou, Eduard Gasal, MD, PhD Lana Shiu MD, PhD MD MD Executive SVP, Clinical SVP, Chief SVP, Global Directo
Slide 99: ORIENT-32: First PD-1 Combo 1L HCC Study
ORIENT-32: Global First PD-1 Combo 1L HCC Study with Fastest Development Progress INNOVENT Sintilimab + Bevacizumab in 1L HCC COVID-19 IND Phase 3 pandemic NDA Approval Deep KOL relationships Approval FPI Pre-NDA NDA submission filing Jun, 2021 Oct, 2018 May, 2019 Rich regulatory experience Oct, 2
Slide 100: ORIENT-16: First PD-1 Combo 1L GC Study
ORIENT-16: China First PD-1 Combo 1L GC Study to Quickly Catch Up and Outrun MNCs and Other Local Players INNOVENT Sintilimab + Chemo therapy in 1L GC IND Phase 3 Predicted NDA Approval FPI Approval Deep disease insight Sept, 2018 Jan 2019 iDMC In 2022 Pre-NDA Closely work with KOLs submission LPI
Slide 101: Conclusion: Bringing Innovative Treatment Options Globally
IR team 【Conclusion】 To bring more innovative treatment options to cancer patients globally Innovent Oncology Development Confidential Copyright© 2021 Innovent 101
Slide 102: Innovent Non-Oncology Development
Innovent Non-Oncology Development 1. Innovent Non-Oncology Strategy 2. Clinical Strategy in Major Disease Area 3. Non-oncology Vision Confidential Copyright© 2021 Innovent Biologics 102
Slide 103: Non-oncology as Another Important Pillar
Non-oncology Represents Another Important Pillar of Innovent’s Overall Pipeline Strategy Huge potentials Innovent non-oncology strategy: unveiled in key disease areas: ● Differentiated anchor asset metabolic diseases, ● Utilize anchor asset to build up franchise ophthalmology, ● Higher standard of c
Slide 104: 2021-2025 Non-oncology Pipeline
2021-2025 Non-oncology Pipeline: From Excellence to Leading Player Franchise & Metabolic disease Eye disease Autoimmune disease Positioning BIC / FIC VEGF-based franchise Dermatology focus Anchor Assets IBI306 IBI362 IBI302 IBI112 Orismilast ● First Domestic ● Global BIC GLP- ● Global rights ● First
Slide 105: Non-Oncology Pipeline Status Overview
Non-Oncology Pipeline Status Overview IND Asset Target Preclinical IND Phase I Phase 2 Phase 3 NDA Launched Approval IBI303 TNF-α Autoimmune IBI112 IL-23 p19 disease Orismilast PDE4 IBI306 PCSK9 Metabolic disease IBI362 GLP-1 / GCGR Eye disease IBI302 VEGF / Complement • Innovent is determined to bu
Slide 106: Innovent Non-Oncology Development
Innovent Non-Oncology Development 1. Innovent Non-Oncology Strategy 2. Clinical Strategy in Major Disease Area 3. Non-oncology Vision Confidential Copyright© 2021 Innovent Biologics 106
Slide 107: Innovent Metabolic Disease Pipeline Overview
Innovent Douran Metabolic Disease 换封面 Pipeline Overview 注射器，血糖仪，听诊器 Confidential Copyright© 2021 Innovent Biologics 107
Slide 108: Unmet Medical Needs for Aging Population and More
Metabolic disease strategy will cover key disease areas: Unmet Medical Needs for Aging Dyslipidemia Hyperglycemia Population and More Gout Geriatric Diseases ......... Healthy Living Confidential Copyright© 2021 Innovent Biologics 108
Slide 109: IBI306: Long-acting anti-PCSK9 Monoclonal Antibody
IBI306: A Potentially Long-acting anti-PCSK9 Monoclonal Antibody Clinical data of early clinical development was IBI-306 Imported PCSK9i Other Domestic accepted by JACC journals Innovent Amgen, Sanofi PCSK9i HeFH Ph3 readout Status Other Ph3 are close to Launched Ph1/Ph2/Ph3 20 readout from baseline
Slide 110: IBI362: Potential Best Molecule for Obesity and Diabetes
IBI362: High Potential to be the Best Molecule Treating Obesity and Diabetes Mechanism of Action Differentiation ● By dually activating GLP-1/GCGR, IBI-362 has shown : IBI362 is a GLP-1R and GCGR dual co-agonist − Significant weight reduction for obesity subjects in Ph1b study with best-in-class pot
Slide 111: IBI362: Weight Loss and Global BIC Potential
IBI362: (In Low / Moderate Dose) Greatly Improves Weight Loss and Showed Global BIC Potential Change in body weight through week 12 in Indirect Comparison with Semaglutide Phase 1b Percent CFB in body weight (%), Percent CFB in body weight (%), 2 0 High dose almost double -1 the benefit and much 0 -
Slide 112: IBI362: Multiple Metabolic Parameters Improvement
IBI362: Brings Multiple Metabolic Parameters Improvement besides Weight Loss And Hyperglycemia Change in LDL-C Change in triglyceride Change in ALT at week 12 at week 12 at week 12 ● In diabetes ph1b study, the findings 5 0.2 0.5 on this parameters improvement are Triglyceride CFB at week 12 ALT CFB
Slide 113: IBI362: High Clinical Performance Compared with Competitors
IBI362: Has Shown High Clinical Performance Compared with Competitors Other domestic Dual IBI-362 (GLP-1/GCGR) TZP(GLP-1/GIP) agonist (Mostly GLP-1/GIP) Pre-clinical Stage Status China Ph2 Global Ph3 No IND Filing ● Diabetes ● Diabetes ● Diabetes Indications ● Obesity ● Obesity ● Obesity ● NASH ● NA
Slide 114: Innovent Ophthalmology Disease Pipeline Overview
Innovent Ophthalmology Disease Pipeline Overview Confidential Copyright© 2021 Innovent Biologics 114
Slide 115: Meeting Needs of Global Patients for Eye Diseases
Meeting the Needs of Global Patients across the Patient Journey for Eye Diseases through Global Innovation Focused ophthalmology diseases: AMD, DME, DR and GA1 Product development Three novel Bispecific Molecules with global rights strategy Initiatives Global vision ● IBI302: For long term vision ma
Slide 116: IBI302: Global FIC Molecule
IBI302: A Global FIC Molecule, Visual Acuity Improvement with Edema Reduction MOA and Differentiation Phase 1: Change of BCVA from Baseline Phase 2: Change of Central subfield Thickness from Baseline Complement components IBI302 * Because of the Covid-19 pandemic, partial data of 4mg group can not b
Slide 117: IBI302: Good Safety Profile and Potential to Inhibit Fibrosis
IBI302: Good Safety Profile and Potential to Inhibit the Progress of Fibrosis and GA Good safety profile: Early stage clinical studies Clinical status: Potential to inhibit the progress of suggested IBI302 was well tolerated in nAMD subjects fibrosis and GA. Phase II study is ongoing Data of SAD was
Slide 118: Innovent Autoimmune Disease Pipeline Overview
Innovent Autoimmune Disease Pipeline Overview Confidential Copyright© 2021 Innovent Biologics 118
Slide 119: On the Way to Autoimmune Portfolio Leadership
Innovent Is On The Way to Autoimmune Portfolio Leadership in China and Global There are large Atopic unmet clinical needs dermatitis in the field of auto- Hidradenitis suppurativa immune diseases Alopecia A best-in-class small Orismilast areata molecule PDE4, can and large market cover a group of (P
Slide 120: IBI112: Best-in-Class IL23p19 Antibody
IBI112: A Best-in-Class IL23p19 Antibody MOA and Differentiation Status in China Drug Name Company PsO UC CD Approved Guselkumab J&J Ph3 Ph3 2019.12 Risankizumab AbbVie NA Ph3 Ph3 Sun.Pharma Tildrakizumab Ph3 NA NA & CMS Mirikizumab Lilly NA Ph3 Ph3 Brazikumab AZ NA NA IND approved IBI112 Innovent P
Slide 121: Orismilast: Development Plan Overview
Orismilast: Development Plan Overview Mechanism of Action & Differentiation Orismilast Differentiated Advantages ● De-risked potential best in class PDE4 in terms of efficacy and AE profile in psoriasis and atopic dermatitis supported with Ph2a results. ● Strong differentiation vs biologics competit
Slide 122: Orismilast (PDE4) Development Plan Overview
Orismilast (PDE4) Development Plan Overview Clinical Highlights Orismilast Development Program Overview Indirect comparison from Ph2a suggests Orismilast oral Share of Psoriasis potential to be ~50% Moderate to severe Psoriasis with 75% more efficacious Clinical than Otezla in ● Ph2b trial (ex-China
Slide 123: Innovent Non-Oncology Development
Innovent Non-Oncology Development 1. Innovent Non-Oncology Strategy 2. Clinical Strategy in Major Disease Area 3. Non-oncology Vision Confidential Copyright© 2021 Innovent Biologics 123
Slide 124: Vision of Innovent Non-Oncology by 2025
Vision of Innovent Broad portfolio driven by global unmet medical Non-Oncology by 2025 needs and innovation Internal Position: Non-Oncology TA become 2nd Pillar of Innovent Excellent global R&D capability External Position: Leading company in Non-Oncology area in China World-class talent and organiz
Slide 125: Commercialization Update & Strategy
Anna Agenda To p i c s 01 02 03 Commercialization Company Overview & R&D and Globalization Update & Strategy Strategy Dr. Michael Yu Strategy Dr. Yong-Jun Liu BD Collaboration Mr. Blake Salisbury Founder, Chairman and CEO President VP 04 05 06 Commercialization Senior Management Pipeline Update Upda
Slide 126: China Biopharmaceutical Market Outlook; Platform Capability in Commercialization
• China Biopharmaceutical Market Outlook • Innovent’s Unique Platform Capability in Commercialization
Slide 127: New Medical Reform Continues to Shed Light on China Drug Innovation
New Medical Reform Continues to Shed Light on China Drug Innovation Trends of Biopharmaceutical Market in China Multi-Level Innovative Drugs Pharma Companies Collaboration& Partnership Health Insurance • Accelerated approvals • License-in oversea tech- • NRDL dynamic management nology platform / ear
Slide 128: China Oncology Market Maintains Strong Growth Momentum
China Oncology Market Maintains a Strong Growth Momentum 80% Global v.s. 4.57 Mn 120 Bn RMB 26% 37% China Number of Oncology Market1 in Oncology Market Oncology Market Share of Target & New Cancer Cases Public Hospitals 5 Year CAGR Antibody Drug2 in 2020, China in 2020, China 2016-2020, China In 202
Slide 129: China Non-oncology Market Also Has Big Growth Potential
China Metabolic, Autoimmune etc. Non-oncology Market also Has Big Growth Potential Top 5/10 Drug Expenditure By Therapeutic Areas Structural 8% Opportunities 15% 8% China vs Global 12% 6% 4% Anti-tumor • Vast unmet medical needs in diseases like 11% 4% Diabetic Pain diabetics, autoimmune, respirator
Slide 130: Innovative Commercialization Approaches Fueled Novel Drugs Penetration
Innovative Commercialization Approaches Fueled Novel Drugs Penetration Multifaceted Ecosystem Involved All Parties • Medical Insurance • Commercial Health Insurance • Market Education Affordability Patient • Pharmaceutical Care • City supplementary Insurance Solutions Benefits (Huiminbao) • Clinical
Slide 131: China BioPharmas Rose to Prominence with Remarkable Sales Growth
China BioPharmas Rose to Prominence with Remarkable Sales Growth MNCs Pharma-cos Bio-pharmas Rich portfolio in Oncology Start from Onco-generics Established a mature oncology Pipelines franchise with innovative products gradually move to innovative portfolio with innovative products & portfolio bio-
Slide 132: Second Growth Trajectory from Diversified Collaboration & Partnerships
Second Growth Trajectory for China Biopharmas Comes From Diversified Collaboration & Partnerships License-in oversea technology License-out local innovation Collaborations of local biotechs platform / early stage assets going global with pharma-cos and bio-pharmas BsAb & U CAR-T Sintilimab (PD-1) Ta
Slide 133: China Biopharmaceutical Market Outlook; Platform Capability in Commercialization
• China Biopharmaceutical Market Outlook • Innovent’s Unique Platform Capability in Commercialization
Slide 134: Full Fledged Commercial Infrastructure
Full Fledged Commercial Infrastructure to Build Up Innovent Commercialization Ecosystem Innovent “3M” and Sales team Sales Marketing MKT Access Medical Solid oncology and product Extensive experience in oncology Good connection with Strong academic background knowledge Solid strategic marketing acad
Slide 135: Proven Commercial Capabilities with Strong Track Record
Proven Commercial Capabilities with Strong Track Record and Promising Anchor Assets Innovent Product Sales Revenue RMB, million 2,500 2,000 CAGR 1,855 +136% 1,500 1,447 BCMA CAR-T PCSK9 1,000 921 （台湾和香港） Early 684 CTLA-4 PI3K Stage 332 Assets 500 …… ROS1/NTRK BCR-ABL 0 2019H1 2019H2 2020H1 2020H2 20
Slide 136: Strong Commercial Potential with Anchor Assets across Core Disease Areas
Strong Commercial Potential with Anchor Assets across Core Disease Areas with Marketed and Late-stage Pipeline Anchor assets Disease Area Target Marketed Late-stage Assets in Phase I/II • LAG3 • PD-1/CD137 LC/HCC/HL PD-1 • PD-L1/LAG3 • PD-1/HER-2 LC/CRC/HCC VEGF • TIGIT • KARS G12C ICC FGFR (Taiwan)
Slide 137: Differentiated Strategies for Established Portfolio and Future Pipeline
Differentiated Strategies for Established Portfolio and Future Pipeline Listed in NRDL Cutting Edge New Launches1 Future Late Life Cycle Assets IBI326 IBI188 IBI306 Pemigatinib Taletrectinib Olverembatinib BCMA-CART CD47 PCSK9 (FGFR) (ROS1) (BCR-ABL/KIT) IBI110 IBI315 IBI315 LAG3 PD-1/HER-2 PD-1/HER
Slide 138: Innovent Commercialization Strategies
Innovent Commercialization Strategies Collaboration with business Accessibility partners A growing scale of commercial team to broaden Collaborations with global and regional coverage players for commercializing innovative pipelines Mission To commercialize high quality biopharmaceutical products th
Slide 139: Accessibility: Growing Commercial Team to Broaden Coverage
Accessibility: A Growing Scale of Commercial Team to Broaden Coverage NRDL and innovative support programs Innovent Commercial Team Expansion enable broad coverage 2,000 Expansion to low tier market enables patients convenience of drug access and improve physician’s medical skill, achieving the visi
Slide 140: Accessibility: Broad HCP Coverage and Portfolio Integration
Accessibility: Strong Synergy with Broad HCP Coverage and Seamless Portfolio Integration Strong synergy with • Innovent existing coverage and HCP engagement in LC, Hema. & HCC, with different subtypes of LC tumors and different targets of Hema. tumor • Seamless portfolio integration will empower pip
Slide 141: Affordability: NRDL & Innovative Ways to Improve Affordability
Affordability: NRDL & Innovative Ways to Improve Affordability Innovative Payment for Accessibility Patient Full Journey Management Early Bird ：Reduction on First Treatment • Capture new patients (“NP”) rapidly，maximize market shares Improve Compliance, Prolong DoT APS(Alternative Price Scheme)： Low
Slide 142: Tyvyt Development Strategies for 5 Big Indications
Innovation: Tyvyt Development Strategies for 5 Big Indications Announced On-going Guidelines & Medical Congress Meetings nsq NSCLC ORIENT 11, 1L sq NSCLC ORIENT 12, 1L ORIENT 3, 2L 1L NSQ WCLC 2020 2021 CSCO IO Clinical Practice Guideline EGFR M+ ORIENT 31, 2L Hepatocellular ORIENT 32, 1L Carcinoma
Slide 143: Comprehensive IIS/RS Study Experience
Innovation：Comprehensive IIS/RS Study Experience to Increase HCPs’ Hands-on Experience Remarkable Achievements 140+ IIS/RS in 2 years Published in Top Journal/Conference IIS RS • Clinical trial studies, published in • Comprehensive experience Lung 12 28 40 Top journals 7 times in IIS/RS study manage
Slide 144: Innovent becomes a Biopharma and a Global Player
Collaboration: Innovent becomes a Biopharma and a Global Player Global collaborations Collaborations with regional player Business Partner Cooperated IBI-348 Taletrectinib Products (BCR-ABL/KIT) (NSCLC ROS1/NTRK) (PD-1) BLA for Tvyvt for 1L • NDA accepted by NMPA • Next generation TKI, potential b
Slide 145: Optimize Patient Benefits, Meet Diversified Needs
Optimize Patient Benefits Meet Diversified Needs Build up a renowned ecosystem Strive for a sustainable growth Leadership in Strategic Competitive Trusted Partner Markets Commercial Capabilities • High value and integrated solutions • Unmet medical needs • Agility to the fast changing market • Long-
Slide 146: Senior Management Panel Discussion
Anna Agenda To p i c s 01 02 03 Senior Management Company Overview & R&D and Globalization Panel DiscussionStrategy Strategy Dr. Michael Yu Dr. Yong-Jun Liu BD Collaboration Mr. Blake Salisbury Founder, Chairman and CEO President VP 04 05 06 Commercialization Senior Management Pipeline Update Update
Slide 147: Confidential
Confidential Copyright© 2021 Innovent 147